Cantor Fitzgerald L. P. Acquires Shares of 12,320 Grail, Inc. (NASDAQ:GRAL)

Cantor Fitzgerald L. P. purchased a new position in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 12,320 shares of the company's stock, valued at approximately $220,000.

A number of other hedge funds and other institutional investors have also modified their holdings of GRAL. Douglas Lane & Associates LLC bought a new position in Grail during the fourth quarter worth about $3,034,000. A. D. Beadell Investment Counsel Inc. acquired a new stake in Grail in the 4th quarter valued at $430,000. FNY Investment Advisers LLC acquired a new stake in Grail in the 4th quarter valued at $26,000. 180 Wealth Advisors LLC bought a new stake in Grail in the fourth quarter valued at $1,681,000. Finally, B & T Capital Management DBA Alpha Capital Management acquired a new position in Grail during the fourth quarter worth $387,000.

Insider Buying and Selling

In other news, President Joshua J. Ofman sold 2,109 shares of Grail stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $31.20, for a total transaction of $65,800.80. Following the completion of the transaction, the president now directly owns 559,673 shares in the company, valued at $17,461,797.60. This trade represents a 0.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert P. Ragusa sold 94,035 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $33.93, for a total value of $3,190,607.55. Following the completion of the transaction, the chief executive officer now owns 734,627 shares in the company, valued at $24,925,894.11. The trade was a 11.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 194,948 shares of company stock valued at $6,583,130 over the last ninety days. 1.85% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Morgan Stanley raised their target price on Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a research note on Tuesday, March 18th. Canaccord Genuity Group began coverage on shares of Grail in a research note on Monday, April 21st. They issued a "buy" rating and a $32.00 target price for the company.

Grail Trading Down 2.5 %

GRAL stock traded down $0.90 during mid-day trading on Friday, hitting $35.20. 878,412 shares of the company were exchanged, compared to its average volume of 1,223,599. Grail, Inc. has a 1-year low of $12.33 and a 1-year high of $63.99. The business has a 50 day simple moving average of $29.54 and a 200-day simple moving average of $25.78.

Grail (NASDAQ:GRAL - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.41) by $2.55. The company had revenue of $38.25 million for the quarter, compared to analyst estimates of $35.33 million. As a group, analysts predict that Grail, Inc. will post -15.15 earnings per share for the current year.

Grail Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.